07 Oct 2025 | 3 Mins Read
Biocon unit gets US FDA approval for stomach treatment tablets
Flipitmoney
Biocon's wholly-owned subsidiary received tentative US FDA approval for the Rifaximin tablets, 550 mg. The tablets are an antibacterial for liver disease and irritable bowel syndrome treatment. The drug was developed in partnership with Carnegie Pharmaceuticals. Biocon shares trade 0.3% higher at $348.65 after the news.